|Articles|August 5, 2016

Pharma Company Selects OmniComm Platform

OmniComm Systems announces the selection of its Trial One platform by a pharmaceutical company to automate its Phase I and BA/BA clinic.

OmniComm Systems announces the selection of its Trial One platform by a pharmaceutical company to automate its Phase I and BA/BE clinic. The company aims to standardize its processes, improve business intelligence, ensure compliance, and transform its overall business within its early phase research.

Read the full release here

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment

ByAndy Studna, Senior Editor

August 12th 2026

© photon_photo - © photon_photo - stock.adobe.com

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

ByMario Alejandro Castellanos Urdaibay, MD, MSc

August 11th 2026

Breaking the Efficacy Ceiling in IBD and Beyond

ByMichael Christel,Kori Wallace, MD, PhD

August 11th 2026

ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program

ByAndy Studna, Senior Editor

August 11th 2026

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

ByRichard Graham, PhD

August 10th 2026

Pharma Company Selects OmniComm Platform

Related Content

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

Breaking the Efficacy Ceiling in IBD and Beyond

ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

Trending on Applied Clinical Trials Online

FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership

Breaking the Efficacy Ceiling in IBD and Beyond

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program